Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …

There is a need for clinical trial end-points to better assess how patients feel and function, so
that interventions can be developed which alleviate symptoms and improve quality of life …

Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are
low. Thus prospective mortality trials are logistically very challenging, justifying the use of …

Background Patients with interstitial lung disease (ILD) require regular physician visits and
referral to specialist ILD clinics. Difficulties or delays in accessing care can limit opportunities …

Background Gastro-oesophageal reflux disease is a potential risk factor for the development
and progression of idiopathic pulmonary fibrosis (IPF). We aimed to investigate the effect of …

Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for
idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count …

Background The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis
(IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or …

Real-world studies include a broader patient population for a longer duration than
randomised controlled trials (RCTs) and can provide relevant insights for clinical practice …

Rationale: Patients with idiopathic pulmonary fibrosis and emphysema may have artificially
preserved lung volumes. Objectives: In this post hoc analysis, we investigated the …